 1. Patients must have persistent signs and symptoms despite the use of prednisone or equivalent at 0.25 mgkgday or 0.5 mgkg every other day, for at least 4 weeks without complete resolution of signs and symptoms. Occasional patients requiring lower doses of prednisone will be eligible if associated with other immunosuppressive drugs. 